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Abstract 
Synthesis of glucosylceramide via glucosylceramide synthase (GCS) is a crucial event in higher 
eukaryotes, both for the production of complex glycosphingolipids and for regulating cellular 
levels of ceramide, a potent anti-proliferative second messenger. In this study, we explored the 
dependence of the early branching eukaryote Giardia lamblia on GCS activity. Biochemical 
analyses revealed that the parasite has a GCS located in ER membranes that is active in 
proliferating and encysting trophozoites. Pharmacological inhibition of GCS induced aberrant 
cell division, characterized by arrest of cytokinesis, incomplete cleavage furrow formation and 
consequent block of replication. Importantly, we showed that increased ceramide levels were 
responsible for the cytokinesis arrest. In addition, GCS inhibition resulted in prominent 
ultrastructural abnormalities, including accumulation of cytosolic vesicles, enlarged lysosomes 
and clathrin disorganization. Moreover, anterograde trafficking of the encystation specific 
protein CWP1 was severely compromised and resulted in inhibition of stage differentiation. Our 
results reveal novel aspects of lipid metabolism in G. lamblia and specifically highlight the vital 
role of GCS in regulating cell cycle progression, membrane trafficking events and stage 
differentiation in this parasite. In addition, we identified ceramide as a potent bioactive molecule, 
underscoring the universal conservation of ceramide signaling in eukaryotes. 
 
Supplementary key words: Glucosylceramide, ceramide, Giardia lamblia, cell division, vesicular 
trafficking, differentitation. 
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Introduction 
Sphingolipids are a highly complex class of lipids in terms of structural diversity, metabolism 
and cellular functions. While initially seen as inert structural components of eukaryotic cell 
membranes, there is now substantial evidence that sphingolipids play an important role in signal 
transduction (for a recent review on bioactive sphingolipids see [1]). 
Ceramide, a central molecule in the sphingolipid biosynthesis, plays a critical role as second 
messenger in cellular signaling which regulates anti-proliferative processes, including apoptosis, 
cell differentiation, and cell cycle arrest in different cell types. Being a highly bioactive 
molecule, ceramide levels must be tightly controlled by diverse coordinated mechanisms, 
including ceramide degradation, phosphorylation or sphingolipid metabolism. Glucosylceramide 
synthase (GCS), also defined as ceramide glucosyltransferase (CGT), metabolizes ceramide to 
glucosylceramide (GlcCer), a glycosylated form of ceramide that does not have anti-proliferative 
activity. GCS plays a crucial role in cell survival after apoptotic stimuli, as demonstrated by the 
up-regulation of GCS and GlcCer in some multidrug resistant tumor cells to counteract a 
chemotherapy-induced increase of ceramide [2, 3]. Conversely, decreased GCS activity by RNA 
interference or by pharmacological inhibition of  GCS activity with PPMP (DL-threo-1-Phenyl-
2-palmitoylamino-3-morpholino-1-propanol) leads to ceramide buildup and  cytotoxicity [4, 5]. 
Thus, GCS is considered a pivotal regulator of bioactive ceramide levels. 
Sphingolipid metabolism in pathogenic protozoa is the object of increasing interest as a source of 
promising chemotherapy targets. We recently showed that PPMP has a potent inhibitory effect 
on Giardia lamblia [6], a protozoan parasite which has undergone massive minimization during 
evolution [7], and is a leading cause of intestinal infection worldwide [8]. Both stages of the 
parasite’s life cycle, namely replicating trophozoites, responsible for pathogenesis, and 
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environmentally resistant cysts, responsible for disease transmission, were affected by PPMP at 
concentrations that are not toxic for mammalian cells. The observed sensitivity to PPMP 
suggested that an active GCS may exist in the parasite; in addition, a GCS homologue, 
GL50803_11642, is annotated in the G. lamblia Genome Database (http://giardiadb.org) and its 
transcription has been reported to be regulated during the parasite’s life cycle [9]. Moreover, the 
predicted ORF GL50803_7598 contains a domain typical of the glycolipid transfer protein 
(GLTP) superfamily. While the precise cellular function of GLTP remains undefined, a proposed 
correlation between presence of a GLTP and GCS activity [10] further supports the presence of 
an active GCS in the parasite. 
However, the synthesis of sphingolipids and of GlcCer in particular has not been demonstrated in 
the parasite so far.  Lipid neosynthesis is limited in G. lamblia, and the parasite is thought to rely 
on lipids taken up from the environment, namely the host intestinal content. Indeed, in vitro 
analyses showed negligible incorporation of lipid precursors, such as acetate and glycerol [11], 
while robust incorporation of exogenous radiolabeled fatty acids [12-14], phospholipids [14] 
ceramide and gangliosides [15, 16] could be demonstrated. In addition, uptake of fluorescent 
sphingolipid  analogues, including ceramide and sphingomyelin, has been reported [12, 14, 15]. 
Importantly, acyl chain desaturation [17], deacylation/reacylation and head group exchange [18] 
have been shown to occur in G. lamblia, indicating that the parasite can remodel the incorporated 
exogenous lipids to fulfill its own needs.  
In this study, we used a biochemical approach to address whether the synthesis of GlcCer occurs 
in G. lamblia and whether it can be inhibited by PPMP. In addition, we investigated the 
molecular mechanism of PPMP-mediated effects in more detail and identified ceramide as a key 
modulator of cellular processes in this parasite. 
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Materials and methods 
Biochemical reagents. Unless otherwise stated, all chemicals were purchased from Sigma and 
cell culture reagents from Gibco-BRL. Inhibitor stock solutions were prepared at the following 
concentrations: 10 mM DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol 
(PPMP), 14 mM fumonisin B1 (FB1), 5 mM myriocin (Myr), 250 mM L-cycloserine (L-cyc), 
22.5 mM N-butyldeoxynojirimycin (NB-DNJ), 3 mM tunicamycin (TM), 16.6 mM nocodazole 
and 20 mg/mL puromycin. Inhibitors were freshly diluted to the concentrations required for the 
individual experiment.  
Parasite cell culture. Trophozoites of the Giardia lamblia strain WBC6 (ATCC catalog number 
50803) were grown axenically as described [6]. Harvested parasites were counted using the 
improved Neubauer chamber. New subcultures were obtained by inoculating 5x104 trophozoites 
from confluent cultures into new 11 mL culture tubes. 
Two-step encystation was induced as described previously [19, 20], by cultivating the cells for 
44 h in medium without bile (pre-encysting medium) and subsequently in medium with higher 
pH and porcine bile (encysting medium). 
Drug treatment of trophozoites was performed on freshly inoculated subcultures. Parasites were 
allowed to adhere for 8 h and then incubated for additional 16 h with the inhibitors at the 
concentrations indicated in the figure legend of the individual experiments. Drug treatment of 
encysting cells was performed in two steps: 7 h drug incubation in pre-encysting medium and 
additional 16 h incubation in encysting medium. For replication and doublet formation assay, 
cells were harvested and counted as described above. 
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For reversibility assay, freshly inoculated subcultures were incubated with the inhibitor for 16 h 
as described above, harvested and washed to remove the drug. Collected parasites were then 
counted and re-inoculated in absence of inhibitor for additional 4 days, followed by counting.  
Expression vector construction and transfection. All constructs of giardial glucosylceramide 
synthase (GCS) (GL50803_11642) were based on the expression cassette C1-CWP for inducible 
expression under the control of the CWP1 promoter [19]. For N-terminal tagging with the 
hemagglutinin (HA) epitope, full length GCS (aa 2 – 537) and variant without putative signal 
peptide (aa 23 – 537) coding regions were amplified by PCR and cloned in a vector containing 
the HA epitope tag upstream of the NsiI restriction site. For C-terminal tagging, the HA epitope 
tag was encoded on the antisense primer and the product cloned into an identical vector variant 
devoid of N-terminal HA-tag. Because giardial GCS coding sequence contains an NsiI restriction 
site, a complementary SbfI restriction site was encoded on sense primers and used for ligation 
into the vectors.  
Stable chromosomal integration of the described constructs was performed using the pPacV-Integ 
expression vector [21] using XbaI and PacI restriction sites. Oligonucleotides (5'-3' orientation) 
used in this study were:  
GCS(2-537)-SbfI-s AGATCTCCTGCAGGACGGGTTGACTCTCTCCTTAGTG; GCS (23-
537)-SbfI-s AGATCTCCTGCAGGCTGTCAACCGCATAAGTG; GCS-PacI-as CGTTAATT 
AATCAGTCGAGGGATTTTTTATTGGCCTG;GCS-HA-PacI-asCGTTAATTAATCACGCGT 
AGTCTGGGACATCGTATGGGTAGTCGAGGGATTTTTTATTGGCCTG. 
Plasmid vector DNA was linearized using SwaI restriction enzyme and 15 µg of digested 
plasmid DNA was electroporated (350V, 960µF, 800Ω) into trophozoites. Linearized plasmid 
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targets the G. lamblia triose phosphate isomerase locus (GL50803_93938) and integration occurs 
by homologous recombination under selective pressure with the antibiotic puromycin [22].  
Gene expression analysis. RNA was isolated from trophozoites or parasites allowed to encyst for 
7 h using an RNAeasy kit (Qiagen, Stanford, CA) following the “Animal Cells Spin” protocol. 
Residual genomic DNA was removed with DNase 1 digestion according to the manufacturer’s 
protocol. The integrity of the RNA was analyzed in a Bioanalyser (Agilent Technologies Inc., 
Palo Alto, CA) with “Eukaryote Total RNA Nano Series II” settings. 
For dual channel microarray analysis, extracted total RNA was processed using the “Amino 
Allyl MessageAmp™II a RNA Amplification Kit”(Ambion, Austin, TX) and labelled with N-
hydroxysuccinimidyl ester-derivatized reactive dyes Cy™3 or Cy™5, according to the 
manufacturer’s protocol. After purification, 2 µg each of Cy3 or Cy5 labelled aRNA were 
denatured, added to SlideHyb™ Buffer I (Ambion), and hybridized to G. lamblia microarrays 
version 1 (TIGR) in a Tecan HybStation at the Functional Genomics Centre Zurich, Switzerland. 
The arrays are epoxy surface coated glass slides with ss-oligo (70 mers) containing 19230 
elements and covering the whole G. lamblia WBC6 strain genome. 
Prior hybridization, slides were hydrated and blocked with 150 µl Tris-HCl-ethanolamine (0.1 M 
Tris, 50 mM ethanolamine, pH 9.0), for 30 minutes at 50°C. After washing, samples were 
injected and hybridized for 16 h at 42°C. Slides were scanned in an Agilent Scanner G2565AA, 
using laser lines 543 nm and 633 nm for excitation of Cy3 and Cy5, respectively. Spatial 
scanning resolution was 10 µm, single pass. The scanner output files were quantified using the 
Genespotter Software (MicroDiscovery GmbH, Berlin, Germany) with default settings and 2.5 
µm radius. The median spot intensities were evaluated with the Web application MAGMA [23] 
and normalized using the print-tip-wise loess correction of the limma package [24]. Potential 
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gene-specific dye-effects were estimated from self-self hybridizations. Differential expression of 
genes during encystation is reported as encystation-induced fold-change, as well as the p-value 
for differential expression as estimated by the empirical Bayes model implemented in limma. 
Experiments were performed in biological triplicate. 
For semi-quantitative real time PCR (RT-PCR), first strand cDNA synthesis was performed 
using ~350 ng RNA and Omniscript reverse transcriptase (Qiagen), according to manufacturer’s 
protocol. Amplification was performed in an iCycler iQ (Biorad, Hercules, CA) using 2 µl of 
1:1000 diluted cDNA. To monitor possible contamination with residual genomic DNA, PCR 
amplification was performed on the extracted RNA and water. Primer pairs (5'-3' orientation) 
used for amplification of actin (ACT), cyst wall protein 1 (CWP1) and glucosylceramide 
synthetase (GCS) were: ACT-s, ACATATGAGCTGCCAGATGG; ACT-as,TCGGGGAGGCCT 
GCAAAC; CWP1s,GGCGATATTCCCGAGTGCATGTG; CWP1as,GTGAGGCAGTACTCTA 
GT; GCS-s, GCAGACCAAGCCTAGCATC; GCS-as, CCTTTACCACAGGCACTTTG. All 
reactions were run in triplicate. To assess the efficiency of the amplification reactions, standard 
curves for every primer pair and cDNA were generated from six-fold serial dilutions in 
duplicate, using the iQ5 software. Expression levels of the genes were given as values in 
arbitrary units relative to the amount of the constitutively expressed house-keeping gene actin. 
Lipid analysis. For analysis of lipid synthesis in G. lamblia in presence of inhibitors, isolated 
parasites were pre-treated with the selected compounds for 30 min at 37ºC followed by labeling 
with 4 µCi/mL [3H]palmitic acid or [3H]serine for 3 h at 37ºC in supplemented PBS (PBS 
containing 50 mM glucose, 9 mM L-cysteine, 1.7 mM ascorbic acid, pH 7.1) in presence of the 
compounds. Labeling with 20 µCi/mL [3H]glucose was performed in supplemented PBS without 
glucose addition. After extensive washing with PBS and 0.05% fat free BSA in PBS, lipids were 
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extracted according to [25]. When required, extracted lipids were saponified by mild alkaline 
hydrolysis. Lipid aliquots were separated by high performance thin layer chromatography 
(HPTLC) on Silica Gel 60 plates. Solvent systems used were the following: A, first dimension, 
chloroform:methanol:25% ammonium hydroxide:water (65:35:4:4); second dimension, 
chloroform:aceton:methanol:acetic acid:water (50:20:10:10:5); B, chloroform:methanol:25% 
ammonium hydroxide (65:25:4.5); C, chloroform:methanol:acetic acid:water (84:4.5:5:0.5) D, 
benzene/2-propanol/water (100:10:0.25). Radiolabeled bands were visualized using a tritium-
sensitive screen (Perkin-Elmer, Boston, USA) in a Personal Molecular PhosphoImager FX 
(Biorad), identified according to co-migrating standards (Avanti Polar Lipids, Alabaster, USA)  
visualized by iodine vapors and quantified using ImageQuant software (Amersham, Otelfingen, 
Switzerland). 
For ceramide glycanase digestion, samples were dissolved in 50 mM sodium acetate buffer pH 
5.0 containing 0.1% (w/v) sodium cholate. Ceramide glycanase (Calbiochem) was added at 
3.1U/mL and digestion was performed at 37oC for 24 h. Lipids were extracted and analyzed by 
TLC. 
For radioactivity incorporation analysis, parasites were labeled with radioactive precursors as 
described. Cell aliquots were solubilized with 0.1N NaOH or processed for lipid extraction; 
whole cell or lipid associated radioactivity was measured by liquid scintillation and normalized 
by protein content. 
Liquid chromatography-mass spectrometry (LC-MS) was carried out using lipids from G. 
lamblia trophozoites, with or without PPMP treatment, and 24 h encysted cells containing an 
average of 33% cysts, as described [26]. Briefly, cells were harvested, washed in PBS, and 
transferred to glass vials. Sphingolipid extracts, fortified with internal standards (N-
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dodecanoylsphingosine, N-dodecanoylglucosylsphingosine, and N-
dodecanoylsphingosylphosphorylcholine, 0.5 nmol each), were prepared as described [27] and 
analysed. The liquid chromatography-mass spectrometer consisted of a Waters Aquity UPLC 
system connected to a Waters LCT Premier orthogonal accelerated time of flight mass 
spectrometer (Waters, Millford, MA), operated in positive electrospray ionisation mode. Full 
scan spectra from 50 to 1500 Da were acquired and individual spectra were summed to produce 
data points each 0.2 s. Mass accuracy and reproducibility were maintained by using an 
independent reference spray by the LockSpray interference. The analytical column was a 100 
mm x 2.1 mm i.d., 1.7 µm C8 Acquity UPLC BEH (Waters). The two mobile phases were A: 
methanol:water:formic acid (74:25:1); B: methanol:formic acid (99:1), both also contained 5 mM 
ammonium formate. A linear gradient was programmed—0.0 min: 80% B; 3 min: 90% B; 6 min: 
90% B; 15 min: 99% B; 18 min: 99% B; 20 min: 80% B. The flow rate was 0.3 mLmin-1. The 
column was held at 30ºC. Quantification was carried out using the extracted ion chromatogram 
of each compound, using 50 mDa windows. The linear dynamic range was determined by 
injecting standard mixtures. Positive identification of compounds was based on the accurate 
mass measurement with an error <5 ppm and its LC retention time, compared to that of a 
standard (±2 %).  
Fluorescence microscopy analysis. Lysotracker Blue-White (Molecular Probes) staining of live 
trophozoites was performed at 100 nM in supplemented PBS at 37oC for 1 hr. Cells were then 
resuspended in PBS and directly imaged. 
For surface labeling, parasites were incubated with 6 µg/mL fluorescein-conjugated cholera 
toxin B subunit (Molecular Probes) in supplemented PBS for 60 min at 4°C and analyzed after 
fixation in 3% formaldehyde solution in PBS for 45 min on glass slides. 
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For membrane endocytosis, parasite were incubated with cholera toxin for 30 min at 4°C, 
washed in PBS, incubated at 37°C for the time indicated in the Figure legends and imaged after 
fixation. Endocytosis was quantified by counting the percentage of cells stained in the 
endocytosis signature area at the centre of the ventral disk. 
For immunolabeling, cells were harvested as described above, washed twice in ice-cold PBS, and 
fixed as before on glass slides. Fixed cells were permeabilized with 0.2% Triton X-100 in PBS 
for 20 min, blocked and incubated with primary antibodies for 1 h. The primary antibodies used 
in this study were: anti-clathrin heavy chain (CLH) mouse antiserum [28], 1:2000 dilution; anti-
protein disulfide isomerase 2 (PDI2) mouse antiserum, 1:1000 dilution; Cy3-conjugated anti-cyst 
wall protein 1 (CWP1) mouse monoclonal antibody (Waterborne, New Orleans, LA), 1:60 
dilution; Alexa488-conjugated anti-HA mouse monoclonal antibody (Roche Diagnostics GmbH, 
Manheim, Germany) 1:30 dilution. Fluorophore-conjugated secondary antibodies were 
purchased from Invitrogen (Basel, Switzerland.) and used at 1: 200 dilution. Microscopy 
analyses were performed on a Leica DM IRBE fluorescence microscope or on a Leica SP2 
AOBS confocal laser-scanning microscope (Leica Microsystems, Wetzlar, Germany), using the 
appropriate settings. Image stacks of optical sections were further processed using the Huygens 
deconvolution software package version 2.7 (Scientific Volume Imaging, Hilversum, NL). 
Three-dimensional reconstruction and surface rendering was done with the Imaris software suite 
(Bitplane, Zurich, Switzerland) using the surpass functions. 
Electron microscopy analysis. Parasite were treated with PPMP or solvent for 16 h and collected 
as described. The cells were resuspended in 2.5 % glutaraldehyde in 0.1M Na/K-phosphate, pH 
7.4, and centrifuged at 3500g for 20 min. After washing, pellets were then postfixed with 1% 
osmium tetroxide in 0.1M Na/K-phosphate for 1 h, dehydrated in a graded ethanol series, 
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transferred to acetone for embedding in epon, and polymerized at 60°C for 2.5 days. Ultrathin 
sections were stained with uranyl acetate and lead citrate and examined at an acceleration voltage 
of 100 kV in a Philips CM 12 transmission electron microscope (Eindhoven, The Netherlands) 
equipped with a low scan CCD camera (Gatan, Pleasanton, USA). 
Determination of protein concentration. Protein content was determined using the Bio-Rad 
Protein Assay according to the instructions provided by the manufacturer. Bovine serum albumin 
was used for the standard curve. 
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Results 
PPMP inhibits glucosylceramide synthesis and increases ceramide levels in G. lamblia.  In 
mammalian cells, PPMP blocks the synthesis of GlcCer by occupying the catalytic site of GCS, 
the enzyme which transfers one glucose molecule to ceramide. PPMP treatment results in 
decreased cellular levels of GlcCer and accumulation of the ceramide  precursor [29]. To 
determine whether G. lamblia is capable of GlcCer synthesis and whether PPMP inhibits GlcCer 
formation in the parasite, we metabolically labeled G. lamblia trophozoites and analyzed the 
extracted lipids by two dimensional thin layer chromatography (2D TLC). Labeling with the 
[3H]palmitic acid precursor showed that 10 µM PPMP, a concentration we previously showed to 
inhibit G. lamblia replication [6], strongly altered the lipid profile by either decreasing (Fig. 1A, 
spots A, B) or increasing (spots C, D) the abundance of labeled lipids or inducing the appearance 
of labeled species not visible in the untreated sample (spot E). Saponification of extracted lipids 
by mild alkaline hydrolysis to remove glycerol-based lipids revealed that lipid “A” was resistant 
to the treatment, and thus supporting that it belongs to the sphingolipid class (Fig 1B).  In 
addition, 1D TLC of saponified samples showed that the predominant band co-migrated with a 
GlcCer standard and its amount decreased upon PPMP treatment (Fig 1C), supporting the notion 
that lipid “A” is GlcCer.  To further confirm that the lipid “A” is indeed GlcCer, the spot was cut 
from the TLC and tested for sensitivity to ceramide glycanase, which hydrolyzes the glucose 
moiety from glycosphingolipids. While the hydrolysis was not complete, TLC separation 
revealed a band co-migrating with ceramide in the glycanase treated sample (Fig. 1D), indicating 
that the lipid in spot “A” is a substrate for the enzyme. In addition, having confirmed that PPMP 
treatment decreased the synthesis of GlcCer in G. lamblia, we next monitored whether GlcCer 
synthesis inhibition resulted in increased cellular levels of the precursor ceramide. TLC 
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separation showed that a band co-migrating with ceramide standard is indeed more abundant in 
the PPMP treated sample (Fig. 1E).  
Similarly to the PPMP-mediated inhibition of G. lamblia replication [6], PPMP inhibition of 
GlcCer synthesis was dose-dependent (Fig. 2A). Importantly, GlcCer synthesis was reduced even 
in cells only pre-treated with 10 µM PPMP for 30 min before drug removal and metabolic 
labeling (Fig. 2A, Pre), suggesting that the inhibitory effect is not reversible. 
Finally, we quantified the reduction of the total GlcCer cellular pool following PPMP treatment. 
Mass spectrometry analysis readily identified the presence of GlcCer in the parasite (Fig. S1). 
PPMP treatment for 4 hrs significantly reduced the amount of less abundant GlcCer species (18:0 
and 20:0). Of note, the abundance of GlcCer species containing long fatty acid residues (22:0 
and 24:0) did not vary in PPMP treated cells, suggesting a different rate of lipid turnover for 
different GlcCer pools (Fig. 2B). Overall, our data show that, similarly to mammalian cells, 
PPMP inhibited GlcCer synthesis resulting in increased cellular levels of ceramide in G. lamblia.  
Metabolic labeling of G. lamblia sphingolipids. G. lamblia is considered to have a limited 
capability for de novo lipid synthesis [30], and only a few candidate enzymes of the sphingolipid 
synthetic pathway are annotated in the parasite genome [9]. Thus, it is not known whether the 
parasite is able to carry out a complete de novo synthesis of sphingolipids or if it relies solely on 
host-derived lipid precursors and/or preformed complex lipids. To determine whether GlcCer in 
cultured Giardia trophozoites derives from de novo synthesized ceramide or from remodeling of 
ceramide taken up from the medium, we metabolically labeled the cells with [3H]serine, a 
substrate for  serine palmitoyl transferase (SPT), the first committing enzyme of sphingolipid 
synthesis which is also annotated in the giardial genome (Fig. S2). Serine was incorporated in the 
parasite three times less efficiently than palmitic acid (Fig. S3), and labeled one major and few 
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minor lipid species, which co-migrated neither with ceramide (Fig. 3A) nor with GlcCer (Fig. 
3B). In contrast with [3H]palmitic acid labeling, all serine labeled species were alkali-sensitive, 
and thus glycerol-based lipids (Fig. 3B). Therefore, under these experimental conditions, serine 
did not label G. lamblia sphingolipids, suggesting that the observed ceramide labeling with 
[3H]palmitic acid is likely to derive from deacylation/reacylation reactions on a pre-existing 
ceramide pool.  
To further elucidate the modality of sphingolipid synthesis, we performed cell labeling with 
[3H]glucose. This labeled molecule was only weakly incorporated into the lipid fraction of G. 
lamblia, accounting for 6% of the whole cell associated radioactivity (Fig. 4B). However, a band 
co-migrating with parasite GlcCer was clearly visible after prolonged TLC exposure (Fig. 3C). 
Similar to the observations during [3H]palmitic acid labeling, PPMP treatment diminished the 
labeling of GlcCer and increased the intensity of other labeled species. 
G. lamblia GlcCer synthesis is not modulated by other sphingolipid inhibitors but by 
tunicamycin. While a homolog of the first committing enzyme of sphingolipid synthesis, SPT, is 
found in G. lamblia, the other enzymes in the ceramide biosynthesis pathway have not been 
annotated in the parasite’s genome, suggesting that giardial sphingolipid synthesis is incomplete. 
We then tested whether known inhibitors of these early steps of sphingolipid synthesis [31] (Fig. 
S2) can inhibit GlcCer formation in the parasite. To do this we performed lipid metabolic 
analyses in the presence of compounds interfering with (i) the first committed step of 
sphingolipid synthesis (20 µM myriocin and 500 µM L-cycloserine), (ii) the synthesis of 
ceramide (50 µM fumonisin B1), and (iii) an additional inhibitor of GCS, structurally unrelated 
to PPMP (400 µM NB-DNJ). In addition, we tested 60 µM tunicamycin, an amphipatic analog of 
UDP-GlcNAc, which was shown to inhibit the synthesis of complex glycosphingolipids in 
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mammalian cells by blocking sugar import into the Golgi apparatus [32-34]. All inhibitors were 
used at the highest concentration of the range used to affect mammalian sphingolipid synthesis. 
Interestingly, of all the sphingolipid inhibitors tested, only PPMP was found to decrease GlcCer 
(Fig. 3D) and to increase ceramide levels (Fig. 3E), while the other compounds did not alter the 
synthetic capability of the parasite. On the other hand, tunicamycin treatment was found to 
increase the GlcCer content without affecting ceramide levels (Fig. 3D, E, S4), suggesting that 
sphingolipid synthesis in the parasite is sensitive to compounds interfering with cellular sugar 
transport. 
Inhibition of GlcCer synthesis promotes lipid turnover. Our previous experiments using tritiated 
palmitic acid and glucose showed that PPMP increased the labeling of several lipid species 
different from GlcCer. Such an increase was further quantified by liquid scintillation analysis of 
the incorporated radioactivity. [3H]palmitic acid incorporation increased both in whole cells and 
in the lipid fraction of PPMP treated parasites compared with control cells (Fig. 4A), suggesting 
that the increased lipid incorporation is accompanied by an increased precursor uptake. 
Interestingly, [3H]glucose incorporation increased in the lipid fraction but not in whole cell 
extracts (Fig. 4A). To test whether palmitic acid and glucose were differently metabolized into 
lipids, we quantified the percentage of whole cell-associated precursors found in the lipid 
fraction. The majority (80-90%) of the cell-associated [3H]palmitic acid was identified in the 
lipid fraction also after PPMP treatment. Conversely, only 6% of the cell-associated [3H]glucose 
was found in the lipid fraction, confirming the limited glucose incorporation reported by [11]. 
However, the amount of lipid-associated glucose increased by 70% in presence of PPMP, 
suggesting that the intracellular glucose pool is relocated toward a lipid synthetic use (Fig. 4B).  
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The previously described inhibitors (Fig. 3D, E) were similarly tested in their capability to 
modulate [3H] palmitic acid incorporation in G. lamblia extracts. Consistent with the 
demonstrated absence of sphingolipid synthesis inhibition, none of the sphingolipid inhibitors 
altered the incorporation of the labeled precursor into both whole cells and lipids (Fig. 4C). 
To identify other lipid classes whose synthesis may be modulated upon PPMP inhibition of 
GlcCer synthesis, we analyzed the pattern of neutral lipids labeled with [3H]palmitic acid. While 
1,2 and 1,3 diacylglycerols (DAG) were the main species present in untreated cells, PPMP 
treatment dramatically changed the proportion of these lipids, increasing 1,2 DAG levels and 
reducing 1,3 DAG (Fig. 4D a, b). The observed alteration of neutral lipid synthesis may have 
been triggered by reduced GlcCer synthesis or increased ceramide levels in PPMP treated cells. 
To discriminate between these possibilities we increased ceramide levels using cell-permeable 
C6 ceramide. In these experimental conditions we observed an increase in both 1,2 DAG content 
(Fig. 4D a, b) and 1,2 and 1,3 DAG ratio (Fig. 4D c), indicating that increased ceramide levels 
contribute to the observed modulation of neutral lipids. 
Increased ceramide levels inhibit G. lamblia cell division. In our previous work, we showed that 
micromolar concentrations of PPMP arrested parasite cytokinesis and induced the accumulation 
of partially divided cells in the culture [6]. To directly correlate the replication inhibition with the 
alteration of sphingolipid synthesis induced by PPMP, we raised the ceramide levels in G. 
lamblia using cell-permeable C6 ceramide, thus mimicking PPMP-induced ceramide increase. 
Incubation with micromolar concentrations of exogenous C6 ceramide severely inhibited G. 
lamblia replication in a dose-dependent manner, with 30 µM completely arresting parasite 
division (Fig. 5A, white bars). Importantly, the concomitant presence of PPMP further inhibited 
parasite replication, indicating that ceramide and PPMP act as agonists on a cellular process 
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which is involved in parasite replication (Fig. 5A, gray and black bars). Furthermore, 
quantitative analysis of C6 ceramide treated parasites revealed that exogenous ceramide induced 
a cytokinesis arrest and accumulation of partially divided cells comparable to the one observed 
during PPMP treatment (Fig. 5B), indicating that increased ceramide levels are sufficient to 
inhibit G. lamblia cell division. 
Similar to the observations described in the lipid analyses above, PPMP was unique amongst the 
sphingolipid inhibitors tested in both blocking parasite replication (Fig. 5C) and increasing the 
amount of partially divided cells (Fig. 5D), while the other inhibitors did not affect neither 
sphingolipid synthesis (Fig. 3D, E) nor parasite cell division (Fig. 5C, D). Furthermore, 
tunicamycin treatment, which increased cellular GlcCer levels, did not alter parasite replication 
and doublet formation, suggesting that increased GlcCer levels alone are not sufficient to 
promote cell division. 
In addition, we investigated the effect of PPMP on cell division in more detail and found that the 
inhibitor exerted a long term block of G. lamblia replication after its removal from the culture 
medium. Parasites treated with the inhibitor for 16 h could not resume cell division even 4 days 
after PPMP removal, whereas control cells reached the density plateau at day 3 (Fig. 5E). The 
plasma membrane of treated parasites was visualized with FITC-conjugated cholera toxin 
(CTX), which binds to the raft-associated sphingolipid GM1 [35]. CTX staining revealed that 
cytokinesis-arrested parasites had properly formed ventral disks (Fig. 5F, arrowheads) but the 
cleavage furrow was mainly absent or, in a minority of cases, incomplete (Fig. 5F, arrows).  
Ultrastructural abnormalities following inhibition of GlcCer synthesis. To examine the 
ultrastructure of G. lamblia upon inhibition of GlcCer synthesis, we compared control cells with 
PPMP treated parasites by thin-section transmission electron microscopy. Consistent with our 
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previous light microscopy observations, we observed an accumulation of partially divided cells 
in the PPMP-treated samples. In addition, in comparison with untreated cells (Fig. 6E), vesicles 
bounded by single lipid bilayer membranes accumulated within the cytosol of PPMP-treated 
parasites (Fig. 6A, arrows and magnified images). Such vesicles had a size of 60-100 nm and a 
non homogeneous electron-density different from the one observed in peripheral vesicles (PVs). 
The vesicles were present as clusters beneath the plasma membrane in close proximity with the 
PVs, juxtaposed to the nuclear envelope, or in the cell interior. PPMP-treated parasites also 
contained conspicuous electron-lucent vacuoles of various diameters (Fig. 6A, B, C, 
arrowheads), often located at the posterior end of the parasites. In addition, several vacuoles 
containing parasite flagella were observed (Fig. 6C asterisks), which have been reported to occur 
in G. lamblia [36] and other anaerobic protists [37] under stress conditions. 
Finally, PVs looked generally more distended in PPMP-treated cells (Fig. 6D) and coiled 
multilamellar structures were also observed, although infrequently (Fig. S5). No gross alterations 
of parasite morphology such as membrane blebbing, ventral disk fragmentation, electron dense 
deposits were observed following PPMP treatment. 
Inhibition of GlcCer synthesis perturbs clathrin localization and endo-lysosomal compartments, 
but does not inhibit membrane endocytosis. We hypothesize that vesicle accumulation detected 
in G. lamblia by electron microscopy may result from altered vesicular trafficking as a 
consequence of exposure to the drug. This hypothesis prompted us to investigate whether PPMP 
treatment affected the morphology of organelles involved in intracellular trafficking processes. 
Firstly, we visualized the parasite clathrin (CLH) which is found closely associated with PVs 
[28], the endo-lysosome system of the parasite [28, 38]. In control cells, the anti-CLH antibody 
stained punctate structures which were uniformly distributed on the dorsal side of the parasite 
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and clustered in selected areas on the ventral side, including the area at the centre of the ventral 
disk (arrow), a signature site for endocytosis  [39] (Fig. 7A). PPMP treatment significantly 
altered the staining pattern and induced aggregation of the punctate structures in the form of 
elongated or circular clusters.  
Next, we monitored the cellular distribution of acidic compartments including PVs in living cells 
after incubation with lysotrackerTM (Fig. 7B). While lysotracker-positive punctate structures of 
homogeneous size were clearly visible in control cells and  were concentrated in the area at the 
centre of the ventral disk (arrow), in PPMP-treated samples this characteristic pattern was not 
observed (dashed arrow). Instead, large structures often located at the posterior side of the cell 
were labeled (arrowhead), most likely corresponding to the large vacuoles observed by 
transmission electron microscopy analysis. 
We then analyzed whether the altered distribution of CLH and lysotracker-positive structures 
observed upon PPMP treatment were linked to changes in the parasite’s ability for endocytosis. 
To this end, we monitored the internalization of cholera toxin (CTX) bound to the plasma 
membrane of trophozoites. In mammalian cells, CTX binds to the raft-associated sphingolipid 
GM1 and enters the cell by retrograde transport in the endocytic pathway [35].  At 4˚C, CTX 
equally labeled the plasma membrane of both control parasites and parasites treated with PPMP 
for 30 min or 16 h, suggesting that the inhibitor did not alter GM1 presence on the plasma 
membrane at the concentration and incubation time used here (Fig. 7C). Following incubation at 
37˚C, CTX was internalized showing a punctate pattern reminiscent of PVs. In particular, CTX 
stained the isolated area at the centre of the ventral disk in a time-dependent manner (Fig. 7C, 
arrow). Importantly, enumeration of cells showing this endocytosis signature site revealed that 
CTX was endocytosed in cells treated with PPMP for 30 min (Fig. 7D, a) or 16 h (Fig. 7D, b) 
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with a kinetic similar to control cells. In addition, mimicking a PPMP–mediated ceramide 
increase with exogenous C6 ceramide did not compromise CTX endocytosis (data not shown).  
Collectively, our data indicate that PPMP incubation profoundly modified the cellular 
organization of CLH and lysotracker positive acidic compartments, suggesting functional 
alteration of PVs. However, neither drug treatment nor exogenous ceramide inhibited 
endocytosis of membrane-bound CTX, which is consistant with a principal roles of PVs in fluid 
phase endocytosis [39]. 
Inhibition of GlcCer synthesis reduces both synthesis and trafficking of encystation specific 
proteins. We previously reported that PPMP treatment affected stage differentiation of G. 
lamblia by inhibiting cyst formation [6]. Here we analyzed the molecular mechanisms of PPMP-
mediated inhibition of parasite differentiation in more detail. Lipid metabolic analyses of 
parasites induced to encyst for 16 or 24 hours revealed that, similarly to trophozoites, 
sphingolipid synthesis was perturbed in presence of PPMP and resulted in decreased GlcCer 
levels (Fig. 8A) and accumulation of ceramide (not shown). 
Next, we monitored whether PPMP affects the fate of cyst wall protein 1 (CWP1), a structural 
protein whose expression, intracellular trafficking and secretion to form the protective cyst wall 
are key steps during the encystation process. To quantitatively assess the effect of PPMP on 
induction of CWP1 synthesis in encysting cells in vitro, we performed population-wide analysis 
of protein expression by flow cytometry 16 h post induction of differentiation. Control cells 
showed an expected substantial increase in CWP1 fluorescence compared with trophozoites 
indicative of protein expression during encystation (Fig. 8B). Conversely, PPMP treated cells 
presented only a modest increase in CWP1 fluorescence, indicating that PPMP severely impaired 
induction of differentiation. Next we tested whether PPMP treatment inhibited not only CWP1 
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expression, but also altered the protein’s intracellular distribution. Immunofluorescence analysis 
of encysting parasites showed that in control cells the protein was mainly localized in doughnut-
shaped encystation-specific vesicles (ESVs) (Fig. 8C). However, in the minor proportion of 
PPMP-treated cells which showed detectable CWP1 levels, the protein was localized in 
numerous elongated structures throughout the cell. Dual staining with the ER-resident protein 
PDI2 revealed that CWP1 positive-structures partially co-localized with the ER. To investigate 
whether the altered organelle distribution of CWP1 was a specific consequence of PPMP 
treatment or a general effect resulting from inhibition of parasite replication and CWP1 
synthesis, we blocked G. lamblia replication with nocodazole [40] and monitored the effect on 
CWP1 localization. Exposure to 6 µM nocodazole during the first 16 h of the encystation process 
inhibited not only replication but also CWP1 synthesis at levels comparable with PPMP 
treatment (Fig. S6). Microscopic analysis showed that nocodazole-treated parasites were 
morphologically altered, lost their drop-like shape and became round with enlarged nuclei. 
However, in a minor proportion of cells which showed CWP1 signal, the protein was localized in 
vesicular structures with typical ESV morphology (Fig. 8D). As in normal conditions at this 
stage of differentiation, no CWP1 was observed in the ER (data not shown). Collectively, these 
data suggest that PPMP treatment specifically impaired not only the induction of CWP1 
synthesis but also the trafficking of the protein from the ER to the cell surface. 
Finally, we tested whether the observed inhibition of G. lamblia encystation derived from 
ceramide accumulation following PPMP treatment. Increasing the cellular levels of this lipid 
using cell-permeable C6 ceramide potently reduced cyst formation (Fig. 8E), suggesting that 
inhibition of encystation following PPMP treatment is likely mediated by ceramide build-up in 
the parasite. 
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Molecular characterization of G. lamblia GCS. Because PPMP’s inhibitory effect is known to 
occur via targeting and inhibition of GlcCer synthase, and a putative GlcCer synthase (GlGCS) 
homolog is annotated in the G. lamblia genome (GL50803_11642), we then focused on the 
characterization of the parasite enzyme. A BLAST database search revealed a number of 
sequence similarities to deduced amino acid sequences of known GCS, and showed a high 
homology to plant enzymes in terms of amino acid identity, protein length (Fig. 9A, S7) and 
hydrophobicity profile (data not shown). Sequence analysis and biochemical data indicated that 
mammalian GCS belongs to the  β-glycosyltransferase family 2 and is a Golgi resident type III 
integral membrane protein with a non cleavable N-terminal signal sequence, which serves as a 
transmembrane anchor, and a long cytoplasmic domain containing the enzyme active site  (rev. 
in [41]). Sequence alignment with selected GCS members indicated that signature sequences of 
the family are conserved in G. lamblia GCS, including a putative N-terminal transmembrane 
domain and a long cytosolic domain (Fig. 9A). Importantly, the G. lamblia sequence contains the 
D1, D2, D3 and (Q/R)XXRW motifs, which are considered essential for catalytic activity [42]. 
Like in the case of mammalian GCS, additional hydrophobic regions are located near the C 
terminus. While various programs for protein secondary structure prediction (e.g. TMpred) 
predict trans-membrane domains in this region of mammalian GCS, no empirical studies have 
been performed to determine the exact topology of this GCS region [42]. 
Mammalian GCS is a Golgi resident integral membrane protein [41].  As G. lamblia lacks an 
identifiable Golgi apparatus [28] but produces developmentally regulated organelles (ESVs) with 
Golgi-like characteristics [21], we then analyzed the localization of GCS in this parasite. To this 
aim, recombinant GlGCS fused to a C-terminal HA tag was expressed in transgenic parasites. 
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Immunofluorescence analysis of stable integrants revealed an intracellular punctuated signal 
reminiscent of ER pattern (Fig. 9B). Co-immunostaining of the ER-resident protein PDI2 
confirmed that GlGCS co-localized to PDI2-positive ER structures in encysting trophozoites 
(Fig. 9B a). Conversely, co-immunostaining of the encystation-specific protein CWP1 revealed 
absence of co-localization with GlGCS, indicating that the protein is excluded from ESVs (Fig. 
9B b,c). 
To investigate the nature of the first N-terminal hydrophobic sequence, HA tags were introduced 
at the N-terminal end either of the full length GlGCS or of a variant lacking the first hydrophobic 
stretch (aa 3-22). Both reporters showed an equivalent signal and distribution, indicating that, 
like the mammalian homologue, the parasite protein is not proteolytically processed to remove 
the first hydrophobic sequence (data not shown). In addition, similar results were obtained with 
HA tagging of the full length protein at the C- terminus, suggesting that the tag position does not 
affect the expression or localization of the recombinant protein (not shown).  
G. lamblia GCS regulation during encystation. To investigate whether GlGCS is regulated 
during parasite stage differentiation, we analyzed the levels of GlGCS mRNA in encysting cells 
at 7 h post induction, the time when RNA transcription of encystation-specific genes peaks [21]. 
Microarray analysis showed a significant increase of mRNA for the sphingolipid synthesis 
enzymes GlGCS and serine palmitoyltransferase 2 in encysting cells compared with trophozoites 
(Fig. 10A). The same RNA samples were also processed for semi-quantitative real time PCR 
(Fig. 10B). The analysis revealed that GlGCS mRNA was less abundant than actin mRNA in 
both trophozoites and encysting cells (actin/GCS ratio<1). Consistent with the microarray data, 
GlGCS mRNA levels increased in encysting cells compared with trophozoites, although the 
observed two fold up-regulation was of moderate proportions relative to the considerable sixty 
 at SM
AC Consortium
 - University of Zürich, on M
arch 10, 2014
w
w
w
.jlr.org
D
ow
nloaded from
 
25 
 
fold up-regulation of CWP1 mRNA. Thus, higher concentrations of GlGCS mRNA were 
detected at 7 hours encystation using two independent methods, suggesting increased GlGCS 
activity during parasite stage differentiation. However, contrary to a previous report showing 
GlcCer accumulation within the cysts by lipid immunostaining [9], our metabolic labeling and 
lipid analysis did not show increased levels of GlcCer during encystation (Fig. 10C). To 
determine whether the sphingolipid composition differed during parasite stage-conversion, lipids 
were extracted from trophozoites and encysting cells and compared by liquid chromatography-
mass spectrometry (LC-MS). The analysis revealed that GlcCer levels were comparable in the 
two stages of the parasite; however, the amount of complex glycosphingolipids and in particular 
of ceramide trihexoside increased considerably in encysting cells (Fig. 10D), revealing that the 
glycosphingolipid composition of the parasite changed during stage conversion. 
Finally, as we showed that both GCS mRNA and complex sphingolipids synthesis are up-
regulated during stage conversion, we hypothesized that GCS over-expression would promote 
parasite encystation. To test this, we assessed encystation efficiency in transgenic parasites 
harboring extra copies of GCS. The analysis revealed that GCS over-expression increased the 
production of cysts compared with control parasites (Fig. 10E), suggesting that GCS activity is 
sufficient to promote the encystation process in this parasite. 
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Discussion 
GCS is a pivotal enzyme in the sphingolipid biosynthetic pathway, acting both as a hub for the 
synthesis of more complex glycosphingolipids and as a regulator of cellular ceramide levels. In 
the present study the role of GCS in the cell cycle and stage differentiation of the pathogenic 
parasite G. lamblia was investigated. We found that pharmacological inhibition of GlcCer 
synthesis increased the cellular levels of ceramide and consequently inhibited cellular 
proliferation and cytokinesis. In addition, GCS inhibition correlated with intracellular trafficking 
defects leading to abortive encystation, indicating that GCS plays a crucial role in parasite’s 
differentiation. 
GlcCer biosynthesis. In mammalian cells, PPMP blocks the synthesis of GlcCer by occupying 
the catalytic site of GCS. In this study we characterized the GlcCer synthesis in G. lamblia and 
its inhibition by PPMP, and found that an active GCS homologue is present in the parasite and 
that sphingolipid synthesis can be targeted by the inhibitor also in this organism. As in 
mammalian cells, inhibition of giardial GCS reduced GlcCer synthesis and induced ceramide 
accumulation. In addition, GCS inhibition increased the overall lipid turn-over in the parasite, 
and, similar to previous observations in mammalian cells [43], increased the synthesis of the 
neutral lipid DAG. Enhanced neutral lipid synthesis may partially offset the effects on membrane 
structure caused by a reduced GlcCer formation; alternatively, DAG accumulation may also be 
the byproduct of increased sphingomyelin synthesis, attempting to lower the levels of ceramide. 
In support of this hypothesis, exogenously provided ceramide also increased DAG synthesis, 
suggesting that the altered neutral lipid synthesis is a compensation mechanism for modulating 
the cellular content of ceramide. 
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While the synthesis of GlcCer was clearly demonstrated in the parasite by metabolic labeling 
with radioactive palmitic acid and glucose, the absence of labeled ceramide when supplying the 
parasites with [3H]serine supported the notion that the sphingolipid synthetic pathway is 
incomplete in G. lamblia and that the parasite uses host-derived ceramide as a substrate for the 
synthesis of complex sphingolipids. Thus, similar to remodeling of phospholipids  in Giardia 
[18], deacylation/reacylation of preexisting ceramide pools  is likely to account for the observed 
[3H]palmitic acid labeling of ceramide. However, it should be noted that serine incorporation in 
the parasite was three times less efficient than palmitic acid. This reduced efficiency, combined 
with the fact that serine is preferentially incorporated into glycerol-based lipids rather than 
sphingolipids in mammalian cells [44], might be a limiting factor in visualizing sphingolipids in 
G. lamblia. Hence, additional labeled precursors should be used to elucidate the lipid synthetic 
steps which are active in the parasite. Intriguingly, while a ceramide synthase is not annotated in 
the G. lamblia genome database, the predicted gene product of GL50803_5939 contains a TLC 
[TRAM/Lag1p/CLN8 (ceroid-lipofuscinoses, neuronal 8)] homology domain (SMART 
accession no. SM00724), which is typical of the Lass (longevity-assurance homologue) family 
members. Lass proteins, homologues to the yeast Lag1p/Lac1p, are highly conserved among 
eukaryotes and function in ceramide synthesis (recently reviewed in [45]). Thus, this G. lamblia 
protein is worthy of careful characterization to elucidate whether a ceramide synthase activity is 
indeed present in the parasite.  
Our metabolic analyses showed that of all the sphingolipid inhibitors tested, PPMP was the only 
compound able to inhibit GlcCer synthesis in G. lamblia. This lack of effect of other 
sphingolipid inhibitors on G. lamblia lipid synthesis can be explained by (i) highly divergent 
parasite enzymes, not efficiently recognized by the inhibitory compounds; (ii) poor inhibitor 
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permeability, as described for fumonisin B1 [31], or (iii) incomplete parasite synthetic pathways, 
lacking the enzymes targeted by the used compounds. Of particular interest is the fact that the 
imino sugar NB-DNJ, a GCS inhibitor structurally unrelated to PPMP, did not affect GlcCer 
synthesis in G. lamblia. NB-DNJ is a promising compound in mammalian cells, which is able to 
reduce GlcCer synthesis  and is currently used as a substrate reduction therapy drug for treating 
type I Gaucher disease [46]. However, this inhibitor is not fully specific, as it inhibits β-
glycosidase I and II as well as GCS, and is a much less effective inhibitor of GCS in vitro than 
the PDMP class of compounds [42]. In addition, NB-DNJ  has been reported to reduce GlcCer 
levels not only by  inhibiting GCS but also by promoting GlcCer catabolism acting as a chemical 
chaperone of GlcCerase [47]; thus the still undefined presence of this enzyme in the parasite and 
its efficient targeting by NB-DNJ  may be crucial for the GlcCer reduction in G. lamblia.  
On the other hand, the increased GlcCer synthesis in the parasite following tunicamycin 
treatment was quite unexpected. In mammalian cells, synthesis of different sphingolipids is 
compartmentalized, with GlcCer synthesis occurring at the cytosolic face of Golgi membranes 
and complex sphingolipids at the Golgi lumenal side. In vivo and in vitro experiments showed 
that tunicamycin inhibits transport of the nucleotide-sugar UDP-Gal into the Golgi and, as a 
consequence, synthesis of complex sphingolipids in the Golgi lumenal decreased and the 
precursor GlcCer accumulated [32-34]. It is not known whether tunicamycin affects nucleotide-
sugar transporter activities in G. lamblia. However, a single nucleotide-sugar transporter specific 
for UDP-GlcNAc was recently described in G. lamblia and, interestingly, this sugar was 
preferentially incorporated into glycolipids rather than into proteins [48]. As tunicamycin is a 
UDP-GlcNAc analog, it is possible that this compound may target the parasite transporter. Thus, 
the GlcCer accumulation observed in G. lamblia following tunicamycin treatment suggests that 
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sphingolipid synthesis may be compartmentalized also in this parasite. This possibility is quite 
interesting as such a compartmentalization would be likely to occur not in the Golgi apparatus, 
which is absent in the parasite [28], but in the ER. In support of this idea, epitope-tagged giardial 
GCS was localized in the ER and in silico analysis showed a putative cytosolic topology of its 
active site; thus, it is likely that GlcCer is synthesized on the cytosolic side of the ER and that its 
translocation to the luminal side may be necessary for further synthesis of complex 
sphingolipids. In this context, it is worth mentioning that, while mammalian GCS is located in 
the Golgi apparatus, the Drosophila homologue is also present in ER membranes [49].  
Ceramide and cell cycle progression. During the inhibition of GlcCer synthesis, G. lamblia 
progressed through rounds of organelle and DNA replication, but was prevented from 
completing cytokinesis and forming a cleavage furrow. A possible explanation for the 
cytokinesis arrest is that inhibition of GlcCer synthesis alters the formation of  sphingolipid-rich 
domains necessary for cytokinesis signaling [50]. However, our results showed that increased 
ceramide levels alone are sufficient to arrest cytokinesis and to block replication in the parasite, 
indicating that ceramide has anti-proliferative effects in the parasite. Moreover, the agonistic 
effect of ceramide and GCS inhibition suggested that GCS acts as a buffer for regulating the 
amount of bioactive ceramide. In this regard, it is interesting to note that the ER, the location of 
giardial GCS, is likely to be the place where prompt regulation of ceramide levels take place, as 
ER structures are indeed the site of ceramide accumulation upon incubation with  an exogenous 
fluorescent analog [15].  
Interestingly, a crucial role of GCS in the pathogenesis of a microorganisms was previously 
decsribed also in the pathogenic fungus Cryptococcus neoformans, where GlcCer was found to 
be a key factor for cell division and virulence [51]. 
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The observed ceramide-mediated inhibitory effects in the parasite following treatment with 
PPMP, is consistent with anti-proliferative and pro-apoptotic effects of PPMP in mammalian 
cells after inducing buildup of ceramide [52, 53]. Studies on the existence of a mechanism 
similar to apoptosis or programmed cell death (PCD) in G. lamblia are scarce. Morphological 
features of PCD following pro-apoptotic drugs, including chromatin condensation, apoptotic 
bodies and cytoplasmic vacuolation, have been reported; however, our understanding of PCD in 
G. lamblia is limited as the parasite does not harbor bona fide mitochondria, key components in 
the apoptotic pathways, and typical PCD-mediating proteins, such as caspases, have not been 
identified in the parasite genome so far [54]. Ceramide is an early mediator of cell cycle arrest 
and apoptosis, acting upstream of caspase-dependent and independent signaling pathways 
(recently reviewed in [55]). Interestingly, putative giardial proteins homologues of  components 
of the ceramide signaling cascade, including protein phosphatases PP1, PI3K/AKT and PP2A, 
[56], are annotated in the Giardia genome data base, and the latter  was shown to be involved in 
the differentiation process of the parasite [57]. Thus it is likely that signaling by ceramide, and 
possibly by other bioactive sphingolipids, is highly conserved also in this simple eukaryote. In 
support of this hypothesis, we found that psychosine, a sphingolipid which induces cytokinesis 
arrest [58] and apoptosis [59] in mammalian cells, also inhibited G. lamblia cell division at 
micromolar concentration (our unpublished results). Collectively, our observations suggest that 
the parasite cell cycle is highly responsive to variations in the cellular levels of bioactive 
sphingolipids. As the molecular mechanisms of ceramide signaling in eukaryotic cells remains 
largely undefined due to the high level of complexity, G. lamblia with its simple organization 
and minimized cellular mechanisms [7] can be exploited as a model system to clarify the core 
components and processes of the signaling machinery. 
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Vesicular trafficking. Recent studies on a variety of organisms revealed that vesicular trafficking 
to the cleavage furrow is an essential process for the completion of cytokinesis (rev. in [60]). Our 
ultrastructural analyses of PPMP-treated samples revealed abnormal accumulations of vesicles, 
whose diameter resembled that of coated vesicles involved in intracellular trafficking. In 
addition, the observed enlarged acidic compartments and aberrant clathrin organization implied 
that defects in intracellular trafficking may occur upon GlcCer synthesis inhibition. Ceramide 
has been proposed to modulate vesicular trafficking in mammalian cells; however, the 
characteristics of this modulation differed in various experimental conditions. Similar to the 
“lysosome phenotype” observed in Giardia, increased ceramide levels have been shown to 
promote the formation of endocytic vesicles and to induce enlarged lysosomes [61]. Enhanced 
endocytosis after ceramide increase via sphingomyelin degradation was also reported [62]. 
Conversely, ceramide increase using exogenous ceramide, sphingomyelin degradation or PDMP-
mediated GCS inhibition,  was shown to compromise fluid-phase endocytosis within minutes  
and to a lesser extent receptor mediated endocytosis [63]. These divergent phenotypes raise the 
possibility that ceramide may differentially regulate endocytic processes in different cell types. 
In our experimental conditions, we found that PPMP treatment altered lysosome morphology and 
clathrin organization but did not reduce nor enhance internalization of CTX bound to the plasma 
membrane. It should be noted that the intracellular transport of CTX does not depend on fluid-
phase endocytosis; instead it requires raft association and involves both clathrin-dependent and 
independent mechanism of endocytosis (rev. in [35]). Thus, it is possible that CTX endocytosis 
in G. lamblia occurs via a modality not sensitive to ceramide. However, in light of the fact that 
fluid phase and receptor mediated endocytosis are differently regulated in the parasite [39], we 
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cannot exclude that intracellular ceramide levels do not modulate other G. lamblia endocytic 
processes. 
Anterograde trafficking of giardial CWP1, a soluble protein which is synthesized during stage 
differentiation and sorted at the level of ER into encystation specific vesicles [28], was clearly 
impaired in presence of PPMP, with consequent reduction of CWP1 deposition on the parasite 
surface and cyst formation. Importantly, treatment with cell permeable C6 ceramide also reduced 
cyst formation, suggesting that increased levels of cytosolic ceramide are sufficient to inhibit the 
encystation process in G. lamblia. 
Studies in mammalian cells more consistently show that raised ceramide levels inhibit 
anterograde trafficking [64-67], suggesting that intracellular ceramide concentration may serve 
as a general modulator of anterograde membrane trafficking events. While it is possible that 
increased ceramide levels in the parasite following GCS inhibition compromise CWP1 
trafficking, it is also conceivable that the reduced concentration of GlcCer plays a role in the 
observed inhibition, as suggested by the increased cyst formation observed during GCS over-
expression. Indeed, glycosphingolipids, most likely GlcCer, are required for the vesicular 
pathway from the Golgi complex to the melanosome (rev. in [68]) . The proposed mechanism is 
that GlcCer on the cytosolic side of Golgi membrane is required for the formation of a functional 
protein coat and subsequent vesicle budding. Thus it is tempting to speculate that in G. lamblia 
GlcCer synthesized by ER-resident GCS may contribute to anterograde protein trafficking by 
either forming membrane microdomains required for sorting of cargo proteins or binding to 
cytosolic proteins which are necessary for recruiting coat proteins and vesicle budding.  
In summary, we have found several novel aspects of sphingolipid metabolism and regulation in 
G. lamblia. Our work revealed that GlcCer synthesis plays a key role in different essential 
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processes associated with the parasite cell cycle and stage differentiation. In addition, we also 
showed that inhibition of GCS blocks parasite cell division, which, together with the likely 
pharmacological discrimination due to low level of giardial GCS identity with the mammalian 
counterparts, validates the potential of this enzyme as a target for drug development.  
Lastly, the presence of an active GCS and the high responsiveness to ceramide in this divergent 
parasite support the hypothesis that GlcCer synthesis and bioactive sphingolipids have conserved 
functions in the regulation of eukaryotic cells processes. In this context, the simple cellular 
system of G. lamblia offers a new perspective from which to explore in details the mechanisms 
of sphingolipid functions and signaling. 
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Figure Legends  
Figure 1:  PPMP inhibits GlcCer synthesis in G. lamblia. Isolated parasites were labeled 
with [3H]palmitic acid for 3 h in presence of 10 µM PPMP or solvent (cntl). A. Lipid 
aliquots corresponding to equal protein amount were separated by 2D-HPTLC using the 
solvent system A. Note the decreased (spots A, B) or increased (spots C, D, E) abundance 
of labeled lipids in presence of the inhibitor. B. Saponification of extracted lipids by mild 
alkaline hydrolysis (NaOH) and separation as described before revealed that lipid “A” 
belongs to the sphingolipids class. C. Saponified lipid aliquots corresponding to equal 
protein amount were separated by 1D-HPTLC using the solvent system B. Note the 
decreased amount of the band co-migrating with a GlcCer standard (GC) upon 10 µM 
PPMP treatment. D. Spot A was cut from the TLC and hydrolyzed with ceramide 
glycanase, as described in the Experimental Procedures section. Samples were then 
separated by 1D-HPTLC using the solvent system B. E. 1D-HPTLC of lipids 
corresponding to equal protein amount using the solvent system C for ceramide (Cer) 
separation. Note the ceramide increase upon 10 µM PPMP treatment. O, Ori, origin. 
Figure 2: Dose-response inhibition of GlcCer synthesis following PPMP treatment. 
Isolated parasites were labeled with [3H]palmitic acid for 3 h in presence of solvent 
(cntl), or PPMP at the indicated concentrations. Alternatively, parasites were pretreated 
with 10 µM PPMP for 30 min, washed and labeled with [3H]palmitic acid as described 
before (Pre). Lipid aliquots corresponding to equal protein amount were separated by 1D-
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HPTLC using the solvent system B. GlcCer (GC) levels are expressed as percentage of 
untreated samples (cntl); data are average ± SE (n=3) of a representative from two 
experiments done in triplicate. B. Liquid chromatography-mass spectrometry analysis of 
glucosylceramides extracted from trophozoites treated for 4 h with of 10 µM PPMP or 
solvent (cntl). Data are average ± SE (n=3). *A significant difference (P<0.05) when 
compared to the percentage of control treated parasites, two-tailed Student’s t-test. 
 
Figure 3: G. lamblia incorporates [3H]glucose but not [3H]serine in GlcCer. A. Isolated 
parasites were labeled with [3H]palmitic acid (Palm) or [3H]serine (Ser) for 3 h and the 
extracted lipids separated by 1D-HPTLC using the solvent system C. For serine-labeled 
samples, lipid aliquots corresponding to three times the protein amount of palmitic acid-
labeled samples were used to compensate for the reduced incorporation efficiency. Note 
the absence of ceramide labeling with serine. B. Extracted lipids were saponified by mild 
alkaline hydrolysis (NaOH) and separated using the solvent system B. Note the complete 
hydrolysis of the serine-labeled lipids. C. Parasites were labeled with [3H]glucose in 
presence of 10 µM PPMP or solvent alone. Extracted lipids were separated using the 
solvent system B. Note the decreased amount of the band co-migrating with GlcCer upon 
PPMP treatment. Ori, origin. D. Isolated parasites were labeled with [3H]palmitic acid for 
3 h in presence of solvent (cntl), 10 µM PPMP, 50 µM fumonisin B1 (FB1), 20 µM 
myriocin (Myr), 500 µM L-cycloserine (L-cyc), 400 µM NB-DNJ, and 60 µM 
tunicamycin (TM). Lipid aliquots corresponding to equal protein amount were separated 
by 1D-HPTLC using the solvent system B or C (panel E). GlcCer (GC) and ceramide 
(Cer) levels are expressed as percentage of untreated samples (cntl); data are average ± 
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SE (n=3) of a representative from three experiments done in triplicate. Note the opposite 
effect of PPMP and TM treatment on GlcCer levels. 
Figure 4: Inhibition of GlcCer synthesis promotes G. lamblia lipid turnover. Isolated 
parasites were labeled with [3H]palmitic acid or [3H]glucose for 3 h in presence of 
solvent (cntl) or 10 µM PPMP. [3H] incorporation was measured in both whole cell 
(TOT) and lipid extracts by liquid scintillation and normalized by protein content. A. 
Incorporation is expressed as percentage of untreated samples (cntl, dashed line); data are 
average ± SE (n=9) of three experiments done in triplicate. Note that PPMP treatment 
increased [3H]palmitic acid incorporation both in whole cells and in the lipid fraction, 
while only in the lipid fraction in the case of [3H]glucose. B. [3H] incorporation in the 
lipid fraction is expressed as percentage of whole cell-associated precursors. Note the 
readily incorporation into lipids of [3H]palmitic acid, compared with [3H]glucose and the 
increased [3H]glucose incorporation upon PPMP treatment. C. Comparison of 
[3H]palmitic acid incorporation in G. lamblia extracts as described in panel A upon 
treatment with solvent (cntl), 10 µM PPMP, 50 µM fumonisin B1 (FB1), 20 µM 
myriocin (Myr), 500 µM L-cycloserine (L-cyc), 400 µM NB-DNJ, and 60 µM 
tunicamycin (TM). Incorporation is expressed as percentage of untreated samples (cntl, 
dashed line); data are average ± SE (n=9) of three experiments done in triplicate. D. 
Isolated parasites were labeled with 4 µCi/mL of [3H]palmitic acid for 3 h in presence of 
solvent (cntl), 10 µM PPMP (PP) or 500 µM C6 ceramide (C6). Lipid aliquots 
corresponding to equal protein amount were separated using the solvent system D. Part a, 
representative 1D-HPTLC. DAG, diacylglycerols, Ori, origin. Part b, quantification of 
lipid levels expressed as percentage of untreated samples (cntl); data are average ± SE 
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(n=6) of two experiments done in triplicate. Part c, ratio of 1,2 and 1,3 DAG upon C6 
ceramide treatment. Data are average ± SE (n=6) of two experiments done in triplicate. 
Note the increase in 1,2 DAG level in PPMP and C6 ceramide treated samples. 
Figure 5: Ceramide modulates G. lamblia cell division. A. Freshly inoculated cultures 
were treated for 16 h with solvent (cntl) or the indicated concentrations of C6 ceramide in 
absence (white bars) or presence of 5 µM (gray bars) or 10 µM (black bars) PPMP. 
Parasites were then harvested and counted; cell numbers are expressed as percentage of 
untreated samples (cntl). Data are average ± SE (n=6) of two experiments done in 
triplicate. Note the agonistic inhibition of parasite replication of C6 ceramide and PPMP. 
B. Parasite cultures were treated with the indicated concentrations of C6 ceramide and 10 
µM PPMP and incompletely divided parasites (doublets) were counted. Results are 
presented as percentage of total parasite number (TOT) ± SE (n = 6) of two experiments 
done in triplicate. Inset: differential interference contrast (DIC) image of a cell doublet. 
C. Freshly inoculated cultures were treated for 16 h with solvent (cntl), 10 µM PPMP, 50 
µM fumonisin B1 (FB1), 20 µM myriocin (Myr), 500 µM L-cycloserine (L-cyc), 400 µM 
NB-DNJ, and 60 µM tunicamycin (TM). Cell numbers are expressed as percentage of 
untreated samples (cntl). Data are average ± SE (n=9) of three experiments done in 
triplicate. D. Parasite cultures were treated as above and incompletely divided parasites 
(doublets) were counted. Doublet number for FB1-treated cells was not determined. 
Results are presented as percentage of total parasite number (TOT) ± SE (n = 6) of two 
experiments done in triplicate. E. Freshly inoculated cultures of trophozoites were treated 
with 10 µM PPMP or solvent (cntl) for 16 h. After drug removal, parasites were 
enumerated daily for the following four days. Results of a representative experiment are 
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presented as average ± SE (n = 6). F. Parasite cultures were treated with 10 µM PPMP for 
16 h and the plasma membrane stained with FITC-conjugated cholera toxin (CTX). Note 
the properly formed ventral disks (arrowheads) and the absent or incomplete cleavage 
furrow (arrows) in incompletely divided parasites. Nuclear staining was performed with 
DAPI. Scale bar: 3 µm. 
Figure 6: Ultrastructural abnormalities following inhibition of GlcCer synthesis. Electron 
micrographs of G. lamblia treated with 10 µM PPMP for 16 h. Note the cytosolic 
accumulation of vesicles (A, thick arrows), the electron-lucent vacuoles of various 
diameters (A, B, C, arrowheads), the presence of vacuoles containing parasite flagella (C, 
asterisks), and distended peripheral vesicles (D). E. Untreated control parasites. N, 
nucleus. PV, peripheral vesicles. Scale bar: 3 µm, except in panel D and right part of 
panel C (0.5 µm). 
Figure 7: Inhibition of GlcCer synthesis alters clathrin localization and endo-lysosomal 
compartments. A. Parasite cultures were treated with solvent (cntl) or 10 µM PPMP for 
16 h and stained with anti-clathrin (CLH) antibody. Note the aggregation of CLH-
positive punctuated structures upon PPMP treatment. Arrow, signature site for 
endocytosis. B. LysotrackerTM staining of acidic compartments in parasites treated as in 
panel A. Note the reduction of the punctuated staining (dashed arrow) and the appearance 
of large structures (arrowhead) in PPMP-treated cells. Arrow, signature site for 
endocytosis. C. Parasite cultures were treated with solvent (cntl) or 10 µM PPMP for 16 h 
and stained with cholera toxin (CTX) at 4ºC to label the plasma membrane. Following a 
37˚C incubation, CTX is internalized and labels the endocytosis signature site (arrow) in 
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both control and drug treated samples. D. Part a, time course of cells treated for 30 min 
with 10 µM PPMP, stained with CTX at 4ºC and showing the endocytosis signature site 
following a 37˚C incubation for the indicated time. Part b, cells were treated with 10 µM 
PPMP for 16 h, labeled with CTX as before and counted for endocytosis signature site-
staining after 90 min of 37˚C incubation. Results are presented as percentage of total 
parasite number ± SE (n = 6) of two experiments done in triplicate. Scale bars: 3 µm. 
Figure 8: Inhibition of GlcCer synthesis perturbs CWP1 trafficking. A. Parasites were 
isolated 24 h post induction of encystation and labeled with [3H]palmitic acid for 3 in 
presence of 10 µM PPMP or solvent (cntl). Lipid aliquots corresponding to equal protein 
amount were separated by 2D-HPTLC using the solvent system A. Note the decreased 
GlcCer levels (spot A) in presence of the inhibitor. B. FACS analysis of parasites 
encysted for 16 h in presence of solvent (cntl) or 10 µM PPMP and stained for CWP1. 
Note the modest CWP1 expression in PPMP-treated samples. T, CWP1-stained 
trophozoites, used as negative control of CWP1 expression. C. Fluorescence analysis of 
parasites encysted for 16 h in presence of 10 µM PPMP or solvent (cntl) and stained for 
CWP1 (red), ER-marker PDI1 (green) and nuclei (blue). Upper images, maximum 
projections; lower images, single optical sections of the deconvolved image stacks. 
Insets: differential interference contrast (DIC) images. Note the co-localization of CWP1 
and PDI2 in PPMP-treated samples. D. Fluorescence analysis of parasites encysted for 16 
h in presence of 6 µM nocodazole and stained for CWP1 (red) and nuclei (blue). DIC, 
differential interference contrast image. Scale bars: 3 µm. E. Parasites were encysted for 
16 h in presence of 10 µM PPMP, 20 µM C6 ceramide or solvent (cntl) and stained for 
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CWP1. Cyst number (out of the total cell number) is presented as percentage of control ± 
SE (n = 3) of a representative from two experiments done in triplicate. 
Figure. 9: Giardial GCS belongs to the β-glycosyltransferase family 2 and localizes into 
ER. A. Protein sequence alignment of GCS orthologues. Black or gray shading indicates 
highly conserved amino acids among all the sequences or between G. lamblia and plant 
GCS, respectively. Indicated are the D1,D2,D3,Q/RXXRW motifs, which are essential for 
enzyme activity as demonstrated by site-directed mutagenesis of mammalian GCS. 
PSORTII predicted transmembrane domains are boxed with solid (strict cutoff) or dashed 
(loose cutoff) lines. Alignments were performed with Multalin (http://bioinfo.genopole-
toulouse.prd.fr/multalin/) and shading was produced with GeneDoc 
(http://www.psc.edu/biomed/genedoc). B. Fluorescence analysis of parasites expressing 
recombinant  giardial GCS fused to a C-terminal HA tag (green) and encysted for 16 h. 
Cells were co-stained for ER-marker PDI2 (part a, red), CWP1 (part b, red), and nuclei 
(blue). Insets: differential interference contrast (DIC) images. Note the GCS co-
localization with the ER marker PDI2 and the absence of co-localization with CWP1. 
Part c, isosurface model of deconvolved confocal image stack showing giardial GCS 
(green) and CWP1 (red). Scale bars: 3 µm. 
Figure 10. Giardial GCS is upregulated during parasite stage conversion. A. Microarray 
analysis at 7 h encystation showing upregulation of the sphingolipid synthesis enzymes 
GCS and serine palmitoyltransferase 2 compared with trophozoites. Upregulation of cyst 
wall proteins is shown as positive control. Gene loci are the following: cyst wall protein 1 
(CWP1, GL50803_5638), cyst wall protein 2 (CWP2, GL50803_5435), cyst wall protein 
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3 (CWP3, GL50803_2421), glucosyceramide synthase (GCS, GL50803_11642), serine 
palmitoyltransferase 2 (SPT2, GL50803_14374), fatty acid elongase 1 (FAE1, 
GL50803_92729). B. Semi-quantitative real time PCR indicating the upregulation of 
GCS and CWP1 at 7 h encystation (EN) compared with trophozoite samples (T). Gene 
expression levels were given as values in arbitrary units relative to the amount of the 
constitutively expressed house-keeping gene actin. Data are average ± SE (n = 3) of a 
representative from two experiments done in triplicate. C. Isolated trophozoites (T) or 
parasites encysted for 24 h (EN) were labeled with 4 µCi/mL of [3H]palmitic acid for 3 h 
in supplemented PBS. Lipid aliquots corresponding to equal protein amount were 
separated by 2D-HPTLC using the solvent systems A. Glucosylceramide (GC) levels 
were expressed as percentage of trophozoite levels; data are average ± SE (n=3) of a 
representative from three experiments done in triplicate. D. LC-MS analysis of 
glycosphingolipids isolated from trophozoites (T) and 24 h encysted cells (EN). GlcCer, 
glucosylceramide; LacCer, lactosylceramide, GM3 ganglioside (sialic acid, galactosyl-, 
glucosylceramide), GD3 ganglioside (sialic acid, sialic acid, galactosyl-, 
glucosylceramide); GGGCer, ceramide trihexoside. Data are average ± SE (n=3) of a 
representative from two experiments done in triplicate. E. Parasites expressing 
recombinant giardial GCS or an empty plasmid (cntl) were encysted for 16 h and stained 
for CWP1. Cyst number is presented as percentage of total cell number (TOT) ± SE (n = 
3) of a representative from three experiments done in triplicate. 
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Figure 3 
 
 
 
 
 at SM
AC Consortium
 - University of Zürich, on M
arch 10, 2014
w
w
w
.jlr.org
D
ow
nloaded from
 
55 
 
Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
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Figure 10 
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